Shell Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $707K | Sell |
|
|||||
|
2025
Q1 | $665K | Sell |
|
|||||
|
2024
Q4 | $852K | Hold |
|
|||||
|
2024
Q3 | $719K | Buy |
|
|||||
|
2024
Q1 | $885K | Buy |
|
|||||
|
2023
Q4 | $386K | Sell |
|
|||||
|
2023
Q3 | $407K | Sell |
|
|||||
|
2023
Q2 | $345K | Sell |
|
|||||
|
2023
Q1 | $457K | Sell |
|
|||||
|
2022
Q4 | $541K | Sell |
|
|||||
|
2022
Q3 | $568K | Sell |
|
|||||
|
2022
Q2 | $643K | Sell |
|
|||||
|
2022
Q1 | $688K | Sell |
|
|||||
|
2021
Q4 | $701K | Buy |
|
|||||
|
2021
Q3 | $658K | Sell |
|
|||||
|
2021
Q2 | $729K | Sell |
|
|||||
|
2021
Q1 | $1.02M | Sell |
|
|||||
|
2020
Q4 | $2.02M | Buy |
|
|||||
|
2020
Q3 | $904K | Hold |
|
|||||
|
2020
Q2 | $1.15M | Sell |
|
|||||
|
2020
Q1 | $1.85M | Sell |
|
|||||
|
2019
Q4 | $2.51M | Buy |
|
|||||
|
2019
Q3 | $1.62M | Sell |
|
|||||
|
2019
Q2 | $1.69M | Sell |
|
|||||
|
2019
Q1 | $1.78M | Buy |
|
|||||
|
2018
Q4 | $1.2M | Sell |
|
|||||
|
2018
Q3 | $2.46M | Sell |
|
|||||
|
2018
Q2 | $2.18M | Sell |
|
|||||
|
2018
Q1 | $1.89M | Buy |
|
|||||
|
2017
Q4 | $1.3M | Buy |
|
|||||
|
2017
Q3 | $712K | Hold |
|
|||||
|
2017
Q2 | $534K | Hold |
|
|||||
|
2017
Q1 | $503K | Sell |
|
|||||
|
2016
Q4 | $591K | Hold |
|
|||||
|
2016
Q3 | $774K | Buy |
|
|||||
|
2016
Q2 | $496K | Buy |
|
|||||
|
2016
Q1 | – | Sell |
|
|||||
|
2015
Q4 | $1.56M | Buy |
|